Serotype-Specific Killing of Large Cell Carcinoma Cells by Reovirus
AbstractReovirus is under development as a therapeutic for numerous types of cancer. In contrast to other oncolytic viruses, the safety and efficacy of reovirus have not been improved through genetic manipulation. Here, we tested the oncolytic capacity of recombinant strains (rs) of prototype reovirus laboratory strains T1L and T3D (rsT1L and rsT3D, respectively) in a panel of non-small cell lung cancer (NSCLC) cell lines. We found that rsT1L was markedly more cytolytic than rsT3D in the large cell carcinoma cell lines tested, whereas killing of adenocarcinoma cell lines was comparable between rsT1L and rsT3D. Importantly, non-recombinant T1L and T3D phenocopied the kinetics and magnitude of cell death induced by recombinant strains. We identified gene segments L2, L3, and M1 as viral determinants of strain-specific differences cell killing of the large cell carcinoma cell lines. Together, these results indicate that recombinant reoviruses recapitulate the cell killing properties of non-recombinant, tissue culture-passaged strains. These studies provide a baseline for the use of reverse genetics with the specific objective of engineering more effective reovirus oncolytics. This work raises the possibility that type 1 reoviruses may have the capacity to serve as more effective oncolytics than type 3 reoviruses in some tumor types. View Full-Text
Share & Cite This Article
Simon, E.J.; Howells, M.A.; Stuart, J.D.; Boehme, K.W. Serotype-Specific Killing of Large Cell Carcinoma Cells by Reovirus. Viruses 2017, 9, 140.
Simon EJ, Howells MA, Stuart JD, Boehme KW. Serotype-Specific Killing of Large Cell Carcinoma Cells by Reovirus. Viruses. 2017; 9(6):140.Chicago/Turabian Style
Simon, Emily J.; Howells, Morgan A.; Stuart, Johnasha D.; Boehme, Karl W. 2017. "Serotype-Specific Killing of Large Cell Carcinoma Cells by Reovirus." Viruses 9, no. 6: 140.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.